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Abstract: Cancer is a group of diseases involving abnormal cell growth. 
The cells grow uncontrollably with the potential to invade and spread to 
other parts of the body. 
This disease is one of the principal death causes in the world, thus becoming 
a significant topic of scientific research. On the other hand, transition metals 
play a fundamental role in different living systems. In particular, Metallo-
drugs represent new and powerful tools for diverse therapeutic applications. 
To date, various metallodrugs display interesting biological activities for 
chemotherapy. In this field, cisplatin was the first inorganic compound with 
high relevance in cancer treatment. This compound was a leader agent in clinical use. Toxic-
ity and resistance problems trigger the development of other platinum drugs with better clini-
cal perspective and also raise the scientific interest for the putative antitumor properties of V, 
Ru and Cu compounds. Several scientific articles show that complexes of these metals are 
the new metal-based drugs used in the treatment of several cancers, such us, lung, colon, 
breast, bladder, etc. 
In this review we recapitulate current information and new advances on antitumor in vi-
tro effects of several organic and inorganic compounds derived from copper, ruthenium 
and vanadium. These metal derived compounds targeting DNA or cell proteins involved in 
cell signaling pathways related to cancer. The mechanisms of cell death of these metallo-
drugs have also been comprehensibly reviewed. 
The knowledge of these mechanisms of death and the relationship between chemical struc-
ture and biological activity may be useful for the design of new metal-based drugs with 
promising pharmacologic applications as anticancer agents. 
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1. INTRODUCTION  
Metal ions regulate a vast array of essential cellular 
processes with high specificity and selectivity. The 
ability of some metal ions to prevent and cure cancer in 
humans has since long been known, with early docu-
mented cases dating back to the 16th century [1]. In  
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this sense, medicinal chemistry has arisen as a field 
covering the design and synthesis of novel drugs, based 
on knowledge related to their function at the molecular 
level. This new prospect enabled the development of 
metal coordination compounds (a) acting as useful 
metallodrugs, which interact with a specific molecular 
target (pharmacodynamics), and (b) being capable of 
reaching that target (pharmacokinetics). Medicinal In-
organic Chemistry has arisen as a field covering the 
design and synthesis of novel drugs, based on the 
knowledge related to the function of metals at cellular 
and molecular levels. This new perspective enabled the 
Please provide 
corresponding author(s) 
photograph
size should be 4" x 4" inches
2    Current Medicinal Chemistry, 2016, Vol. 23, No. 30 León et al. 
development of metal coordination compounds (a) act-
ing as useful metallodrugs, which interact with a spe-
cific molecular target (pharmacodynamics), and (b) 
increasing through coordination the possibility to reach 
the cellular and molecular targets (pharmacokinetics). 
The extensive range of coordination numbers, phys-
icochemical properties, redox states and geometries, of 
the metal ions and ligands enable different reactivities 
that are useful tools for research in this field. Consider-
ing these facts, Inorganic Biochemistry presents good 
opportunities for the design of appropriate therapeutic 
agents [2,3]. Furthermore, this area has taken advan-
tage of carbohydrate derived ligands to increase the 
solubility and molecular targeting of metallodrug can-
didates. As a result of such activity, a significant num-
ber of anticancer metal based drugs have emerged in 
the last years [4-6]. Outstanding such metallodrugs are 
platinum complexes. It is worthy to mention the suc-
cess of cisplatin in medicine for the treatment of sev-
eral kinds of tumors. Its use positioned the metallo-
drugs in an interesting place for cancer treatment [3, 7]. 
Cis-[Pt(NH3)2Cl2] (cisplatin) has been used in a signifi-
cant number of cancer with high incidence in society 
but it is usually combined with radiation or other medi-
cation. Different metallodrugs that have been used for a 
cancer treatment have a similar mechanism of action of 
cisplatin and the design and synthesis of these are 
based on structural similarities with cisplatin.  
On the other hand, serious side effects and resis-
tance limit the therapy with cisplatin [8]. New discov-
eries in drug design try to reduce toxicity and also open 
the range of tumors to be treated with some compounds 
[9,10]. In fact, the disadvantage of cis-Pt has been par-
tially ameliorated by the use of new platinum drugs 
such as carboplatin and oxaliplatin [11]. Cancer has 
been and remains to be considered yet as one of the 
fatal diseases worldwide. Cancer is the general name of 
any malign neoplasia and involves more than 100 dis-
eases which share an uncontrolled growth of cells that 
invade organs and tissues placed even at a distance 
from the original tumor (metastasis) [12]. Cancer cure 
requires deep knowledge of the processes initiating and 
developing the chemical and biological phenotypes of 
the disease. The main features of cancer comprise sev-
eral biological skills that involve the capacity of evad-
ing growth suppressors, resisting cell death, inducing 
angiogenesis, invasion and metastasis, and evading 
immune system [13]. The study of these concepts is 
expected to increase and stimulate the design and syn-
thesis of new metal based drugs with anticancer proper-
ties and development of alternative therapies. 
Among the ten most active metal derived drugs it is 
worthy to discuss vanadium compounds [14]. In the 
case of vanadium, notable is the presence of vanado-
cene, a promising anticancer agent belonging to the 
family of metallocenes [15]. However, other forms of 
vanadium, extending from simple inorganic salts to 
more defined coordination compounds involving or-
ganic and inorganic ligands have also been proposed as 
anticancer agents [16,17]. Future work will help to de-
cide on their applicability in the fight against cancer, 
based on the strict chemical criteria governing solubil-
ity, bioavailability and molecular specificity at the sub-
cellular level. Other interesting metal based drugs with 
potential anticancer properties are ruthenium deriva-
tives [18,19]. Ruthenium is particularly attractive as the 
ligand exchange kinetics in its complexes can be simi-
lar to those of platinum complexes [20]. Several scien-
tific reports show the interaction of ruthenium com-
pounds with different molecular targets such us DNA, 
mitochondria, among others[21,22]. Another metal in-
teresting pharmacological properties and different tar-
gets for cancer treatment is copper [23]. Copper is an 
endogenous metal with important functions. It is know 
that these kinds of components may be less lethal for 
cells with normal phenotypes than for tumor cells. 
Nevertheless, copper can also be toxic due to its affin-
ity for binding sites and redox effects. The transformed 
metabolic processes of tumors provoke differential re-
sponses to copper compounds comparing to normal 
cells [6]. In this present survey, the state of knowledge 
referred to copper, ruthenium and vanadium derivatives 
with potential anticancer effects has been reviewed.  
2. ANTITUMOR ACTIVITY OF VANADIUM 
COMPOUNDS  
In the last years, the antitumor activity of several 
vanadium derivatives has been remarked, but the 
mechanisms of action are not well understood. The 
principal molecular targets for the anticancer effects of 
vanadium compounds are the disruption of cellular me-
tabolism through the generation of ROS, the depletion 
of GSH, the alterations of cellular organelles, the spin-
dle key proteins such as cyclins, cytoskeleton proteins, 
some signal transduction pathways and caspases, which 
in turn play a role in cell cycle arrest and programmed 
cell death.  
2.1. Vanadocenes  
Within metallocenes field, one of the most impor-
tant metal based drug are titanocenes and derivatives. 
The anticancer activity of titanocene dichloride was 
widespread in the early of 1980. Then, this compound 
Vanadium, Ruthenium and Copper Compounds Current Medicinal Chemistry, 2016, Vol. 23, No. 30    3 
was studied in phase I clinical trials in 1993 [24] and 
while phase I clinical trials were not as satisfactory, 
several phase II clinical trials with patients with breast 
and a renal tumor have been carried out detecting a 
very low activity [25]. Nevertheless, in the last ten 
years, different works of many groups showed that 
these kinds of metals exhibited anticancer activity to-
ward several types of tumor such us prostate [26], cer-
vix, melanoma, colon and lung, and these results re-
newed the interest in this field [27-29]. 
The biological results showed that titanocene Y 
(bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) 
dichloride) and C (Bis-(N,N-dimethylamino-2(N-meth-
ylpyrrolyl) methylcyclopentadienyl) titanium (IV) di-
chloride) are the most promising metallodrugs as anti-
tumor agents and in particular show promise for use in 
combination therapies. The main mechanism of action 
of these compounds involved to induce apoptosis in a 
dose-dependent manner, induce DNA damage and a 
differential damage response and reduced the clono-
genic capacity of the cells without affecting the cell 
cycle progress in prostate tumor cells. Besides, Titano-
cene Y activated cell signaling affected c-Jun N-
terminal kinase and it increased the phosphorylation 
levels of adenosine monophosphate (AMP)-activated 
protein kinase α1 (AMPKα1) in small lung cancer 
cells. On the other hand, Titanocene Y triggered apop-
tosis in leukemia cells, regardless of the expression of 
anti-apoptotic Bcl-2 and pro-apoptotic smac. Moreo-
ver, the titanium compounds are also effective against 
leukemia cells that are multidrug resistant due to over-
expression of P-gp [30]. 
Other interesting group of compounds with antitu-
mor properties within metallocenes field are vanado-
cene derivatives [31]. Vanadocene, is a metallocene, 
belonging to a group of organometallic derivatives, 
with a metal ion sandwiched between two cyclopenta-
dienyl rings. The first vanadocene that showed relevant 
pre-clinic results was the bis(cyclopentadienyl) di-
chloro-V(IV), vanadocene dichloride, [VCp2Cl2] (1), 
[32]. This compound exhibits a higher in vitro activity 
against tumor cell lines upon direct comparison with 
[TiCp2Cl2] (2) (see Fig. 1). Besides, in vivo studies re-
vealed that vanadocene compounds exhibit significant 
antitumor properties with vanadocene dichloride being 
one of the most promising among metallocenes [33]. 
Recently, speciation studies have shown that [VCp2Cl2] 
transforms at physiological pH to [VCp2(OH)2] and 
carbonate, oxalate, lactate, phosphate are able to dis-
place the two OH- ions to yield the adducts with these 
ligands [VCp2(ox)], [VCp2(CO3)], [VCp2(lactH(-1))], 
and [VCp2(HPO4)] [34]. Several vanadocene deriva-
tives, especially the methyl-and methoxy-substituted 
vanadocene dichlorides showed cytotoxic effects 
against T-lymphocytic leukemia cells with MOLT-4 
evidencing more activity than their corresponding tita-
nocene analogs. Activation of apoptosis by vanadocene 
compounds is very similar to the mechanism used by 
cisplatin, as it triggers DNA injury and involves p53 
activation [35]. p53 is a tumor suppressor factor that 
normally functions in apoptotic mechanisms, cell cycle 
regulation, and maintenance of genomic stability. 
VCl Cl TiCl Cl
 
Fig. (1). Schematic structures of vanadocene dichloride (1) 
and, titanocene dichloride (2). 
On the other hand, vanadocenes are efficient agents 
against human testicular cell lines [36]. Vanadocene 
compounds containing phenanthroline (phen) ligands 
are promising chemotherapeutic agents, mostly due to 
their high anticancer activity, solubility and stability 
properties [37]. In recent years, scientific reports have 
shown the design and synthesis of new benzyl-
substituted vanadocenes, including 3, 4 and 5 which 
were modeled after bis-[5-(p-methoxybenzyl) cyclo-
pentadienyl] titanium(IV) dichloride (Titanocene Y) 
and its derivative compound (6) (Fig. 2). The three va-
nadocene caused slightly better activity than cis-platin 
in several cancer cell lines [38]. Besides, other novel 
compounds such as benzyl- substituted vana-docenes 
with p-methoxybenzyl)cyclo-pentadienyl], bis-[(3,4- 
dimethoxybenzyl)cyclopenta-dienyl] and bis-[(3,4,5-
trimethoxybenzyl)cyclopenta-dienyl] showed high tox-
icity on pig kidney epithelial cell line [39].  
2.2. Vanadium IV and V Complexes  
Another interesting class of vanadium compounds 
with potential application in cancer treatment is formed 
by some oxidovanadium(IV) complexes. One of the 
most important and promising example in this area is 
bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovana-
dium (IV) Metvan (Fig. 3). This complex induces cell 
damage through apoptosis activation in several human 
cancer cell lines such as multiple myeloma cells, leu-
kemia cells, and solid tumors derived from breast, 
ovarian, prostate and testis [4,40,41]. One of the main 
therapeutic advantages of Metvan is the high effective-
ness toward ovarian and testicular cancer cell resistant
4    Current Medicinal Chemistry, 2016, Vol. 23, No. 30 León et al. 
V
Cl
Cl
O
O
VCl Cl
OCH3
OCH3
OCH3
OCH3
V
Cl
Cl
O
O
O
O
O
O
V
Cl
Cl
O
O
O
O
3
4
5
6
 
Fig. (2). Schematic structures of bis(η5-(2-methoxybenzyl) 
cyclopentadienyl)-vanadium(IV) dichloride (3), bis( η5-(3,4-
dimethoxybenzyl)cyclopentadienyl)-vanadium(IV) dichloride 
(4),bis(η5-(3,4,5-trimethoxybenzyl)cyclopentadienyl)-vanad-
ium (IV) dichloride (5), and bis(η5-(3,4-dimethoxy-benzyl) 
cyclopentadienyl)-titanium(IV) dichloride (6). 
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Fig. (3). Schematic structure of bis(4,7-dimethyl- 1,10-phen-
anthroline) sulfatooxovanadium(IV) “Metvan”. 
to cisplatin. On the other hand, Metvan shows promis-
ing anticancer actions on glioblastoma and breast can-
cer in invivo models. The wide range of Metvan anti-
tumor activity with auspicious pharmacodynamics fea-
tures and its low toxicity highlight that this compound 
has potential to be the first vanadium complex as an 
alternative to the classical platinum treatment [42]. 
Flavonoids are a group of natural polyphenols pre-
dominantly synthesized by higher plants with numer-
ous pharmacological properties. The main therapeutic 
actions of flavonoids include antiviral, anticancer, anti-
bacterial and antioxidative activities [43]. On the other 
hand, metal complexation has an important role in the 
improvement of the pharmacological activities of metal 
ions. The anticancer properties of a series of flavonoids 
(quercetin, hesperidin, morin, silibinin, chrysin) and 
their complexes with oxidovanadium(IV) were investi-
gated against normal (MC3T3E1) and tumor 
(UMR106) osteoblasts-like cells [44-46]. Table 1 high-
lights the effects of flavonoids and VO-flavonoids 
complexes against normal (MC3T3E1) and tumor 
(UMR106) osteoblasts-like cells. The comparison was 
performed at 100 µM concentration. As it can be seen, 
hesperidin, quercetin and silibinin only altered slightly 
normal osteoblasts whilst chrysin produced a cytotoxic 
effect on proliferation of these cell lines and this effect 
could be probably attributed to structural differences 
due to the lack of substituents on B ring of the cyn-
namoyl system. In view of these previous results, 
VOsil and VOchrys (Fig. 4) have been thoroughly in-
vestigated in the human osteosarcoma cells (MG-63). 
This cell line is an excellent model to study the effects 
of potential anticancer drugs for osteosarcoma treat-
ment. In human osteosarcoma cells, oxidovana-
dium(IV), chrysin and VOchrys impaired cell viability 
in a concentration-dependent manner. Moreover, VO-
chrys was the strongest antitumor drug in human os-
teosarcoma cells having a lower IC50 value (16 µM) 
than vanadyl cation and chrysin ( >100 µM) [47]. In 
addition, in the same cell line, VOsil, decreased the cell 
viability in a dose dependent manner with a greater 
potency than silibinin and vanadyl cation. The complex 
also displayed a concentration effect both in cyto- and 
genotoxicity processes. Investigation of the redox 
status of the cells was determined through the ROS 
level and GSH/GSSG ratio. These parameters were the 
most representative for the events involved in the dele-
terious effects of the complex on human osteosarcoma 
cells. Moreover, the compound induced cell cycle ar-
rest (G2/M phase) and the activation of caspase 3 that 
conveyed the cells to apoptosis [48]. From the com-
parison of the anticancer properties of VOchrys, VOsil 
and cisplatin in MG-63 cells, it could be concluded that 
VOchrys was the strongest antiproliferative effects (see 
Table 2). Table 2 gives IC50 values of VOchrys, VOsil 
and cisplatin in MG-63 cell line. ROS generation, al-
terations of the GSH/ GSSG ratio, changes in the mito-
chondria membrane potential (MMP), induction of 
caspase-3 and DNA damage are the main mechanisms 
involved in the antitumor activity of VOchrys and 
VOsil. 
All these mechanisms finally trigger the human os-
teosarcoma cells to apoptosis. Besides, VOchrys and 
VOsil showed promissory anticancer effects against 
human colon adenocarcinoma cells. These vanadium 
compounds caused cytotoxicity and genotoxicity in a 
concentration dependent manner. The main mecha-
nisms of action of VOchrys involved a decrease in 
GSH/GSSG ratio and cell cycle deregulation whilst 
VOsil employed several mechanisms that include a 
decrease in GSH, programmed cell death activation, 
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Table 1. Effects of flavonoids and VO-flavonoids complexes against normal (MC3T3E1) and tumor (UMR106) os-
teoblasts-like cells. 
Flavonoids MC3T3E1  (%)  
basal  
(100 µM) 
UMR106  (%) basal  
(100 µM) 
Vanadyl and 
VO-flavonoid com-
plexes 
MC3T3E1 (%) 
basal  
(100 µM) 
UMR106  (%) basal  
(100 µM) 
   (VO)2+  71 115 
Hesperidin 90 85 VOhesp 20 20 
Quercetin 95 78 VOquer 60 82 
Silibinin 94 60 VOsil 46 33 
Chrysin 65 40 VOchrys 50 42 
Morin 70 65 VOmor 30 65 
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Fig. (4). Schematic structures of oxidovanadium(IV) com-
plexes with chrysin (VOchrys) and silibinin(VOsil). 
Table 2. IC50 values of VOchrys, VOsil and cisplatin on 
MG-63 cell line. 
Compounds IC50 
VOchrys 16 µM 
VOsil 74 µM 
Cisplatin 43 µM 
attenuation of NF-kB pathway among others [49]. An-
other interesting group of vanadium based drugs com-
plexes of oxidovanadium(IV) with ligands that hold 
multiple donor atoms is able to coordinate with metal 
centers. 
Chelating ligands are relevant in living systems 
since they can facilitate the uptake and transport of 
metallodrugs inside the cells. Oxodiacetate (oda), 
O(CH2COO-)2, is a very versatile ligand that coordi-
nates metal ions by forming chelate rings [50]. VIVO-
complexes of oda, VIVO(oda), as well as VIVO 
(oda)(bipy) and VIVO(oda)(phen) (Fig. 5), showed sig-
nificant effects in osteoblast like cells. The three com-
plexes were tested in two cell lines derived from os-
teoblasts (MC3T3-E1 from mouse calvaria and 
UMR106 from a rat osteosarcoma cells). VIVO (oda) 
inhibited cell viability in both cell lines, but the inhibi-
tory effect was stronger in the normal than in the tumor 
osteoblasts [51]. The principal mechanisms of action 
involved in the anticancer activity of VIVO(oda) are 
ROS generation, depletion of GSH, disruption of the 
mitochondria membrane potential (MMP) and acti-
vated ERK cascade phosphorylation [51]. Besides, 
VIVO(oda)(phen) impaired cell viability in both cell 
lines (MC3T3-E1 and UMR106), but the cell damage 
was stronger in the normal than in the tumor cells [52]. 
On the contrary, VIVO(oda)(bipy) showed promissory 
antitumor activity since the cytotoxicity was stronger in 
the tumor than in the normal cells [53]. Recent reports 
have shown that the three complexes caused a concen-
tration dependent inhibition of cell viability in human 
osteosarcoma cells in culture [54]. In this order, 
VIVO(oda)(phen) produced strong cytotoxicity affect-
ing several organelles such us lysosomes and mito-
chondria from 2.5 µM) while VIVO(oda) and 
VIVO(oda)(bipy) only caused these effects at higher 
concentrations (100 µM). Moreover, complex with 
phen and bipy derivatives triggered apoptosis as a rele-
vant mechanism of cell death. Besides, the nuclease 
activity of the three compounds revealed that DNA 
cleavage caused by VIVO(oda) and VIVO(oda)(bipy) 
was similar, whilst VIVO(oda)(phen) showed a stronger 
effect. In this way, a very interesting relationship be-
tween the bioactivity of the complexes and their struc-
6    Current Medicinal Chemistry, 2016, Vol. 23, No. 30 León et al. 
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Fig. (5). Schematic structures of oxidovanadium(IV) com-
plexes with oxodiacetate VO(oda), oxodiacetate and 2,2 
bipiridine VO(oda)bipy, oxodiacetate and 1.10 phenantroline 
VO(oda)phen. 
tures was achieved. VIVO(oda)(phen) showed the most 
potent anticancer action in human osteosarcoma cells 
followed by VIVO(oda)(bipy) and subsequently by 
VIVO(oda)) in agreement to the number of intercalating 
heterocyclic moieties [54]. Others organically chelated 
vanadium compounds also showed interesting antican-
cer activity against lymphoma derived cells. Quinoline 
and pyridinone molecules are attractive ligands because 
of their pharmacological activity. The antitumor ac-
tions of quinoline complexes on U937 cells showed 
slight relation with the length and shape of the alkyl 
chain in the relationship structure-activity analysis 
[55]. One of these compounds showed stronger antitu-
mor effects than cisplatin. Moreover, this complex ac-
tivated apoptosis but through a pathway independent of 
caspase activation [55]. Besides, hydroxiquinoline de-
rived vanadium complexes displayed specifically anti-
cancer activity against cisplatin sensitive/resistant ovar-
ian cells (A2780/A2780cisR). The bioactivity of these 
vanadium compounds toward the A2780 cell line was 
dependent on incubation time and concentrations show-
ing IC50 values in the range of 3-14 µM. In this order, 
these compounds were significantly more active than 
cisplatin (22 µM), in the A2780 cells and in the cis-
platin-resistant cells A2780cisR (4-8 µM vs. 75.4) [56]. 
A huge family of vanadyl compounds also includes 
bound organic ligands based on the salen ligand. A 
pyridoxal-based vanadium(IV) complex showed selec-
tive cytotoxicity for tumor cell lines in contrast with 
healthy cells. The complex impaired cell viability was 
stronger in melanoma and lung carcinoma cells than in 
normal epidermal keratinocytes, lung cells and periph-
eral blood mononuclear cells [57]. Oxidovanadium 
(IV) complexes with a Schiff base and thiosemicarba-
zones as mixed- ligands showed interesting antitumor 
effects on several colon cancer cell lines (HTC-116, 
Caco-2, and HT-29) and also with non-cancerous colo-
nic myofibroblasts (CCD18-Co). In general, these com-
pounds exhibited antitumor activity on cancer cells, but 
did not affect normal cells. Nevertheless, compounds 
8-10 (Fig. 6) showed less inhibitory effects on CCD- 
18Co cells, suggesting a possible cytotoxic selectivity 
against colon cancer cells and may have a potential in 
chemotherapy (see Table 3) [58]. Table III shows 
Antitumor activity of compounds derivatives 8-10 and 
cisplatin, on different colon adenocarcinoma cell lines 
after 24, 48, and 72 h of treatment. Data are expressed 
as IC50 ( µM). IC50 values are shown as mean ± S.D. 
obtained from three independent experiments. Others 
organic vanadium complexes with pharmacological 
activities are acetylacetonate derivatives. 
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Fig. (6). Schematic representations of oxidovanadium(IV) 
complex with with a Schiff base and thiosemicarbazones (7) 
and different thiosemicarbazones derivatives of ligands (8, 9, 
10).  
Oxidovanadium(IV) complexes with ferrocenyl-
terpyridine and acetylacetonate ligands exhibited selec-
tive antitumor effects in cervix and breast cancer cell 
lines (HeLa and MCF-7) with low cytotoxicity in nor-
mal fibroblast 3T3 cells [59]. Moreover, Vanadyl 
bisacetylacetonate (VO(acac)2) arrested cell cycle at 
G1 phase in a concentration- and time-dependent man-
ner in hepatocarcinoma cells. The phosphorylation of 
ERK and Akt pathways was greatly activated and these 
are two major mechanisms of action related to the anti 
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Table 3. Antitumor activity of compounds derivatives 8–10 and cisplatin, on different colon adenocarcinoma cell lines 
after 24, 48, and 72 hours treatment. Data are expressed as IC50 ( µM). IC50 values are shown as mean ± S.D. 
from three independent experiments. 
HT-29   Caco-2   
Compounds 
24 h 48h 72h 24 h 48h 72h 
8 277.1±10.2  239.6±7.9 100.3±5.1 349.1±19.5 277.1±16.3 147.1±10.8 
9 244.2±8.8  169.6±15.1 87.9±0.5 367.0±21.5 281.6±14.4 152.5±12.7 
10 128.6±10.7  82.4±9.6 47.8±5.5 242.1±25.1 166.2±15.3 85.4±14.0 
Cis-Pt 84.7± 1.9  80.6± 1.6 69.1±3.2 32.0± 1.6 22.8± 1.5 17.9±1.8 
 HCT-116   CCD18Co   
 24 h 48h 72h 24 h 48h 72h 
8 203.4±7.7  181.3±9.2 115.0±6.5 495.6±23.5 339.2±16.7 208.0±11.9 
9 227.4±6.8  192.7±11.6 110.3±10.1 490.6±27.6 329.5±15.4 203.6±12.5 
10 161.3±4.6  134.9±3.9 89.5±14.5 382.7±21.9 246.2±11.4 152.2±12.0 
Cis-Pt 53.8±2.1  49.7±1.3 41.0±2.7 83.0±1.1 72.0±1.5 64.1±1.6 
 
cancer activity of the complex [60]. On the other hand, 
several VV-compounds were reported to exhibit antitu-
mor properties in different experimental models 
[4,14,16]. The development of V(V)-peroxide species 
in binary as well as ternary combinations emerged as a 
promising approach for novel cancer therapy. To this 
end, different V(V)- peroxide complexes have been 
designed and synthesized as potential antitumor com-
pounds. The most common form of a bis(peroxido) 
vanadium complex is M[VO(O2)2L]n·xH2O and that of 
a mono(peroxido)vanadium complex is M[VO(O2)L] 
n·xH2O. In peroxidovanadate complexes, the peroxido 
ligands are bound to the vanadium center almost exclu-
sively in a side-on fashion in which the geometry 
around vanadium is octahedral or pentagonal bipyra-
midal, with varying numbers of water molecules or 
hydroxido ions. In vitro assays showed that peroxido-
vanadium complexes displayed inhibitory effects of 
protein phosphotyrosines suggesting that the effects of 
protein phosphotyrosines are one of the key mecha-
nisms of action of peroxidovanadium complexes as 
antitumor agents [61]. V(V)-oxido and V(V)-oxido-
peroxide compounds with carboxylic acids K3[VO(O2) 
(C2O4)2]·1/2H2O and K3[VO2(C2O4)2]·3H2O containing 
oxalate ligands showed interesting anticancer activity 
against human osteosarcoma cells. In this way, the mo-
noperoxide complex showed a very strong antitumor 
action, whereas the dioxide compound was inactive 
[62]. Moreover, bis(peroxido)vanadium(V) complexes 
like (Pr4N)[VO(O2)(ox)(phen)] (Vphen)[ox = oxalate 
(2-) and Pr4N+= tetra(n- propyl)ammonium], promote 
DNA cleavage in human lymphocytes in a concentra-
tion- dependent manner [63]. Further screening of 
probable anticancer activity on a murine leukemia cell 
line (L1210 cells) showed that they exhibited signifi-
cant antitumor activity in a concentration and exposure 
time-dependent manner [63]. Several peroxide species 
were investigated in order to identify correlations of 
organic ancillary ligands with their related structures 
and the relationship to the physiological and antitumor 
effects. The nature and denticity of employed ligands 
were variable adopting a pentagonal bipyramidal ge-
ometry around the vanadium ion in these compounds. 
This geometry is typical for a monoperoxido V(V) spe-
cies with an organic ancillary ligand. In addition, half-
maximal inhibitory concentration (IC50) values in dif-
ferent cancer cell lines could be related to the transition 
energies (LMCT) of the peroxide group, especially 
among complexes with analogous ligands. Djordjevic 
proposed that intramolecular electron transfer between 
the peroxide group and the metal center would affect 
the anticancer activity of the peroxidevanadium species 
and these result were in agreement [29]. It is suggested 
that ROS generated through intramolecular electron 
transfer in V(V)- peroxide species, may be one of the 
mechanisms of action responsible for the observed cy-
totoxicity. V(V)-peroxide species bearing variable 
ligands show different antitumor actions and these ef-
fects may be ascribed to the distinct electronic contri-
bution of the bound peroxide moiety. Therefore, cyto-
toxicity and physiological actions of V(V)-peroxide 
species, correlating structure and activity, can ride 
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strongly on the nature and electronic properties of the 
auxiliary ligand, thus guiding the design and synthesis 
of new peroxidovanadium compounds that may be 
used as anticancer agents [64,65]. On the other hand, 
anthraquinone derivatives compounds exhibited spe-
cifically higher inhibition on human colorectal adeno-
carcinoma (HCT-8 cells) than the clinical anticancer 
drug Fu-5. Along the same lines, the anticancer activity 
of three different vanadium complexes bearing pyridi-
none Schiff and pyrimidinone-based ligands (Fig. 7) 
was studied in two different cell lines. The study 
showed that the V(V)-species resulting from the V(V)- 
MHCPE are more toxic for tumor cells (HeLa) than for 
normal cells (3T3-L1 fibroblasts), thereby indicating 
potential anticancer activity [66,67]. Other relevant 
Schiff base with pharmacological properties is N,N' 
bis(salicylidene)ethylenediamine, more commonly re-
ferred to as salen. VO-salen (Fig. 8) inhibited K562 
leukemia cell proliferation in the range of 6-32 µM and 
the complex enhanced taxol anticancer activity. These 
conclusions support that the combined use of VO-salen 
and taxol might establish an effective novel approach 
against leukemia [68]. Semicarbazones are versatile 
ligands with therapeutic effects. Different semicarba-
zones and vanadium complexes were tested in three 
different human tumor cell lines derived from breast, 
colon and kidney cancer for then activity as potential 
anticancer drugs, showing selective antitumor activity 
on kidney derived cells. Results showed that changes in 
the semicarbazone moiety structure could have a rele-
vant effect on the antitumor activity of the vanadium 
complexes [69]. Moreover, a complex of vanadium(V) 
with salicylaldehyde semicarbazone (V(V)-Salsem) 
(Fig. 9) exhibited anticancer effects on tumor os-
teoblasts through the production of ROS, the ERK 
pathway activation and the apoptosis induction [70].  
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Fig. (7). Schematic illustration of plausible forms of com-
plex V(V)MHCPE. 
2.3. Polyoxovanadate compounds 
Polyoxometalates (POMs) are clusters with transi-
tion metal oxygen anion that contain combinations of 
metal cations (usually the d0 species V(V), Mo(VI), 
and W(VI)) associated by oxide anions. The structural, 
electronic and physicochemical properties (shape, sta-
bility under physiological conditions, polarity, redox 
potential, etc), make them attractive for different uses 
in diverse fields. POMs have pharmacological proper-
ties as antiviral and anticancer agents [71,72]. 
Polyoxovanadates are a prominent subclass of POMs 
that are relatively less investigated in comparison to the 
Mo and W compounds. These compounds show differ-
ent topologies and structures such as [V4O12]4-, 
[V5O14]3- and [V10O28]6- [73]. Other important features 
of polyoxovanadates are their diverse structural chem-
istry, combining tetrahedral (VO4), square pyramidal 
(VO5) and octahedral (VO6) units, a variability of oxi-
dation states and the potential encapsulation of small 
molecules or ions. 
V
O
N
O
O
N
 
Fig. (8). Schematic representation of  VO-salen. 
O
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Fig. (9). Schematic structure of vanadium(V) complex with 
salicylaldehyde semicarbazone (V(V)-Salsem). 
Polyoxovanadates form diverse anionic species in 
solution that can coexist simultaneously in equilibrium, 
like mononuclear [VO4]3-, dinuclear [V2O7]4-, tetranu-
clear[V4O12]4- and decanuclear [V10O28]6-. The pH of 
solutions is a relevant property to study the speciation 
of oxovanadates. In this sense, a decrease in pH in-
creased the generation of the protonated forms. The 
pharmacological effects of polyoxovanadates include 
antiviral, antibacterial and antitumor activities. Scien-
tific reports showed the antitumor activity of octa-
cosaoxidodecavana-date(V)Na4Co(H2O)6V10O28·18 H2O 
(CoV10) against liver and ovary cancer cell lines [74]. 
Moreover, octacosaoxidodecavanadate(V) diammo-
nium derivatives, (H2tmen)3V10O28·6H2O and (H2en) 
3V10O28.2H2O, decreased the cell viability showing a 
high anticancer activity in lung adenocarcinoma and 
leukemia cells [75]. The structures of these compounds 
are very similar (skeletal structure of octacosaoxidode-
cavanadate(V) anion and cation), however, the main 
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difference is the four methyl (CH3) substituents of 
cation in the former species. Therefore, the compound 
(H2tmen)3V10O28·6H2O has higher anticancer activity 
since its amphiphilic structure facilitates its permeation 
through the monolayer cell membrane. In the last year, 
several mixed-valence V(IV)/V(V) octacosaoxidode-
cavanadates were interestedcompounds due to their 
structural, spectroscopic, nuclease activity and DNA- 
protecting actions. One of the more relevant com-
pounds is (Me4N)6[V15O36Cl] that have important 
chemical interaction properties with alkylating agents 
[76]. Different DNA interaction studies showed the 
chemoprotective action of this compound toward alky-
lation agents such as diethylsulphate (DES) and di-
methylsulphate(DMS) using pUC19 plasmid DNA. 
The main mechanism of action elucidated for this che-
moprotective activity exposed the progressive genera-
tion of V(IV), V(V) and mixed-valence aggregates, 
suggesting mechanistically preferential transfer of the 
alkyl group to the vanadate instead of DNA [76]. One 
of the most important biomedical polyoxovanadates are 
the decavanadate derivatives [V10O28]6- that play a key 
role in many biological processes [77]. These com-
pounds may act as effective ion pump inhibitors and 
have the potential therapeutic applications in the treat-
ment of different diseases such us cancer, diabetes, 
ischemic heart disease, ulcers, etc. [78]. Recently sci-
entific reports showed the antidiabetic actions of met-
forminium decavanadate (H2Metf)3[V10O28]·8H2O in 
Wistar rats as biological model. This compound has 
therapeutic properties as a hypoglycemic, lipid-lowe-
ring and metabolic regulator [79]. Considering other 
promising biological roles of these kinds of com-
pounds, several groups reported novel synthesis of dif-
ferent polyoxovanadates based on decavanate structure 
[80,81].  
3. ANTITUMOR ACTIVITY OF RUTHENIUM 
COMPOUNDS  
Historically, cisplatin discovery opened the perspec-
tive to use drugs with a metal core for cancer treatment, 
despite its good effects over tumor cells, it also showed 
a narrow therapeutic window, with severe and undesir-
able side effects on patients [1]. This safety issue with 
the cisplatin raised the number of investigations related 
to platinum and non-platinum metallodrugs in order to 
find substances capable of killing cancer cell but with 
better toxicological profile. Within the transition metal 
group, the platinum like elements have played an im-
portant role in the research and development of new 
active pharmaceutical ingredients (API). Among them, 
ruthenium (Ru) showed attractive chemical properties 
like its range of oxidation states (8, 6, 4, 3, 2, 0 and -2), 
atomic radius and the variable kind of ligands that can 
form complexes or bonds with Ru. Especially for the 
medicinal chemistry, the oxidation states 3 and 2 have 
a particular importance due to their stability under 
physiological pH and the equilibrium between those 
species make them suitable for potential pharmaceuti-
cal uses [82]. The ruthenium compounds with biologi-
cal interest can be classified into the following main 
categories: coordination and organometallic ruthenium 
derivatives.  
3.1. Coordination Compounds  
As models of coordination compounds, the well-
known and vastly explored NAMI-A, KP1019, KP418 
and NKP-1339 were found. The main feature in these 
complexes is related to their six-coordinated sphere of 
coordination, achieving an octahedral geometry, where 
ligands containing soft nitrogen and sulphur atoms (e.g. 
imidazole, indazole and DMSO) are found in the axial 
positions and are the responsible of the steric and elec-
tronic properties of the complex [83,84]. Four axillary 
positions, occupied with ligands can be easily replaced 
or exchanged (e.g. chloride), depending on the envi-
ronmental conditions (see Fig. 10). The interaction of 
these complexes with blood components in vitro and in 
vivo, proved strong relation between the ability of the 
complexes to bound to serum albumin and transferrin 
with their pharmacokinetic profile and the final thera-
peutic effect. Such proteins have a main role in trans-
portation and storage of ruthenium complexes [85]. In 
the case of trans-tetrachloridobis(1H-indazole) ruthen-
ate(III)], Jarosz et al. showed that the complex can bind 
to transferrin in apo and holo forms, out of the Fe bind-
ing site and is still recognizable by the transferrin re-
ceptor in the cell [86]. Some studies about ruthenium 
complexes reviewed by Pessoa and Tomaz demon-
strated that the presence of transferrin-complex adducts 
enhanced the anticancer activity of the complexes [87]. 
This highlights the importance of this protein in the 
mode of action. The Ru-transferrin adduct reaches the 
tumor cell, almost in a targeted way, since it is known 
that cancer cells have a higher need of iron and it has 
been proved that this causes an overexpression of trans-
ferrin receptor on the cell surface [88-90]. This ap-
proach led to the development of this kind of com-
plexes (protein adducts) as a “Trojan horse” (Fig. 11). 
The activation by reduction of Ru (III) to Ru (II) is the 
currently accepted hypothesis by which the complexes 
of Ru (III) act as a pro-drug (see Fig. 12). It is believed 
that the complexes once released from the transport 
proteins in zones with low pressure of oxygen (acidic 
10    Current Medicinal Chemistry, 2016, Vol. 23, No. 30 León et al. 
N
NH
N
HN
Ru
ClCl
ClCl
-
H+
N
HN
KP1019
N
NH
Ru
S
O
Cl
Cl
Cl
Cl
-
N
H+
NH
NAMI-A
 
Fig. (10). Structure of KP1019 and NAMI-A. 
environment) are reduced to Ru(II) complexes which 
are more reactive and ready to interact with proteins 
(imidazole nitrogen from histidine side chains) or nu-
cleobases (nitrogen 7 in the purine bases) into the cell 
[82,91]. The mechanism of action for these complexes 
actually goes beyond the DNA cross-linking and ad-
ducts formation previously investigated [92]. There is 
some evidence that this kind of compounds also cause 
a disruption in the mitochondrial and cellular redox 
balance by producing reactive oxygen species (Fenton-
like reaction) and GSH depletion. Different carried out 
experiments suggested that the addition of ROS scav-
engers reduce the cytotoxicity of these complexes [93-
96]. However, the most accepted mechanisms of action 
based on KP1019 and NKP-1339, are redox balance 
disruption, cell cycle arrest on G2/M, DNA synthesis 
blockage and finally apoptosis induced mitochondrial 
pathway [91]. As previously exposed, the ability to ex-
change ligands in the coordination sphere for the Ru 
complexes, and the possibility to induce modifications 
in their structure are the key factors to achieve a ra-
tional design of drugs and the establishment of struc-
ture activity relationship [97]. Since the mechanism of 
action of Ru (III) drugs is conservative in many com-
pounds, the keystone in the investigation is more re-
lated to the characteristics of the ancillary ligands, aim-
ing to improve pharmacokinetic behavior [98]. Another 
subfamily of the Ru coordination compounds is that 
composed of complexes containing at least one 
polypyridyl ligand (e.g. bipyridine or phenanthroline). 
The accepted mechanism of action of these drugs is the 
binding and cleaving of DNA inducing apoptosis in the 
cancer cells [99]. At normal physiological conditions, 
at least one of the polypyridyl ligands will remain in-
ertly bound to the Ru center. This could be extended to 
the case in which every ligand in the complex is inert 
to hydrolysis reactions and therefore the coordination 
sphere of the metal remains saturated. In this last situa-
tion, the mechanism of the cytotoxicity should be dif-
ferent from that known for other metallopharmaceuti-
cals (i.e. the activation by hydrolysis step is not viable).  
3.2. Ru-Arene Complexes (Organometallic) 
A second class of Ru related compounds, which 
have gained an important place in the research field of 
medicinal chemistry are the Ru-Arene complexes. The 
main concern about Ru (II) complexes is related to the 
stability and the ligand exchange rate. Nevertheless, 
Sadler and coworkers found out that arene moiety acts 
as a stabilizer of the Ru atom and increases the lipo-
philicity, which can increase the uptake by the cell en-
hancing the cytotoxic effect [100]. The Ru(II)-arene 
complexes have the general formula [(ƞ6 - arene)Ru 
(X)(Y)(Z)] where X (e.g. Chloride) is a leaving group, 
and YZ are chelating ligands [101]. In general, the cy-
 
Fig. (11). Schematic representation of the overexpression of transferrin receptor on tumor cells and the possible delivery 
mechanism and recognition mediated by transferrin-Ru adduct. 
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totoxic effect increases in function of the size (lipo-
philic character) of the arene ligand, probably related to 
the capability to intercalate with the DNA. In this or-
der, the bicyclic arenes showed higher rate of DNA 
damage compared with the single cycle arenes, and this 
effect is linked with the ability to form arene base π-π 
stacking (see Fig. 13) [102-104]. The ligands occupy-
ing the position (Y)(Z), have an important role in the 
antitumor activity since it was demonstrated that 
monodentate ligands have lower activity compared 
with chelated ligands in the inclusion of ethylendia-
mine, which led to an increase in the biological activity 
even on cisplatin resistant cell lines [105,106]. Studies 
varying the chelating ligand with N-N, N-O and O-O 
groups revealed that the anticancer activity of com-
plexes with N- N moiety was stronger than N-O and O-
O [107, 108]. These complexes should be in an active 
form, capable of interacting with the molecular target 
(mainly attributed to DNA). The most described activa-
tion mechanism is the aquation, where the leaving 
group (chloride or another halide) is substituted by a 
water molecule. [(ƞ6 - arene)Ru(!)(Y)(Z)] → [(ƞ6 
arene)Ru(H2O)(Y)(Z)]. In the bloodstream the com-
plex with halide is mostly kept in an inactive form due 
to high chloride extra cellular concentration (c.a. 100 
mM). However, when the compound enters to the cell, 
the Cl- concentration is about 4 mM which facilitates 
the replacement of the leaving group by the water 
molecule [104,105,109]. The rational design of com-
plexes allows to set up the rate and extend of hydroly-
sis based on the properties of the arene, leaving the 
group and the chelate ligand. This is a useful tool to 
control the selectivity and half-life of the complex 
[110].  
3.3. RAPTA Compounds 
This class of compounds have a stabilization 
mechanism mediated by arene moiety, the family of 
([Ru (η6-arene)(PTA)X2], PTA = 1,3,5-triaza-7-
phosphaadamantane). 
benzene
> > > >
p-cymene9,10-dihydroanthracene
1,1'-biphenyl1,4,9,10-
tetrahydroanthracene  
Fig. (13). Chemical structures of arene moiety sorted in de-
creasing order of anticancer activity. 
Chemically these compounds are configured as fol-
lows: three Ru coordination positions are occupied by 
the arene ligand, a position is filled by the PTA 
(phosphine) ligand which gives it a hydrophilic (water 
soluble) character and two positions with labile ligands 
(mainly chloride) which are available for aquation acti-
vation (see Fig. 14) [111]. These compounds have a 
low cytotoxic effect in vitro, but in further investiga-
tion it was found that they have a similar property to 
inhibit the metastasis process similar to the NAMI-A 
[112]. RAPTA-C suffers a rapid aquation driving to 
very high activation [109]. Modification of the core 
using bidentate ligands instead of Cl- leads to an in-
crease in the stability, solubility and aquation rate 
(carbo-RAPTA and oxalo-RAPTA). In relation to the 
molecular target of these complexes, it is very interest-
ing that RAPTA-C shows a selective pH dependent 
damage of DNA on acidic environment (pH< 7). In this  
 
N
N
N
P
Ru
Cl
Cl
A
PTA
R RAPTA
 
Fig. (14). Representation of the structure of RAPTA. 
 
Fig. (12). Scheme of the potential mechanisms of action and transport. 
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order, scientific reports showed that DNA damage in 
tumor cells (acidic pH) is higher than in healthy cells 
(neutral pH). This effect can be attributed to the PTA 
ligand protonation at low pH,which is a more active 
form of the RAPTA-C compound [109]. The RAPTA 
complexes do not show selective in vitro binding to 
DNA, proteins and RNA [89]. But, this complex inhib-
ited cell growth and division through G2/M arrest and 
apoptosis induction [113]. In Fig. (15), the first mem-
bers of the RAPTA series of compounds are displayed. 
Dyson and collaborators made modifications in the 
arene ring and the PTA moiety to evaluate the structure 
activity relationship,these changes increased the stabil-
ity and led to control the aquation process and enhance 
the cytotoxic and antimetastic activity [111]. Neverthe-
less, Ru-Arene complexes overshadowed the investiga-
tions related to these complexes due to their better cy-
totoxic profile compared with the RAPTA family. Un-
doubtedly, the ruthenium complexes and compounds 
have proven be potential tools for the development of 
future therapeutics for cancer treatment. A develop-
ment in Ru based drugs is an open door to a rational 
design where the flexibility to change the ligands led to 
find new cellular targets, enhancing the selectivity of 
the compounds. A great number of Ru compounds 
have been synthesized and their cytotoxic effects on 
several tumor cell lines have been demonstrated, de-
spite the heterogeneity in their chemical structure. 
However, it should be noted that the effect of the lipo-
philic ligands, which in the most of the cases induced a 
strong anticancer effect on solid tumors, even with IC50 
lower than those obtained with cisplatin. (see Table 4). 
Nowadays the action mechanism of Ru metallodrugs is 
quite unclear, but scientific studies pointed out some 
targets recognized for the different compounds (see 
Fig. 16) [83]. Table 4 shows the structure-activity on 
several tumor cell lines of different ruthenium com-
plexes. [114-127]. 
3.4. Ru Complexes: Role in Photodynamic Therapy 
(PDT). 
Among the practical applications of Ru complexes 
as alternative to the cancer treatment, beyond chemo-
therapy, photoactivated chemotherapy (PACT) and 
photodynamic therapy (PDT) have gained a notorious 
relevance in the last decade. According to SCOPUS® 
database in 2006, two documents related to Ru and 
photodynamic therapy were published, whilst in 2015, 
thirty-three scientific articles were published. 
The photodynamic therapy (PDT) is the approach 
which mostly studied the cases of anticancer drugs ac-
tivation through light which can be split into two cate-
gories: photoactivated chemotherapy (PACT) and pho-
todynamic therapy (PDT). 
The photodynamic therapy requires the presence of 
three agents: a photosensitizer (PS), light and molecu-
lar oxygen (O2). The first one is a molecule with the 
ability to be excited by light in the range of 650 to 800 
nm. The activation yields an electron displacement to 
higher energy levels with the subsequent energy release 
as fluorescence emission, phosphorescence or a non-
radioactive decay, called intersystem crosslinking. 
[128-130] 
The excited PS can be present as singlet state and 
/or triplet state, and produce two types of reactions. 
The type I: derived from an excited singlet state in-
volves the oxidation or the reduction of the substrates 
or even the photosensitizer itself to produce superox-
ide, hydroxyl and peroxides radicals which can start the 
cascade of cytotoxic effects leading to the cellular 
death. The type II: involves the presence of the excited 
triplet state, produced by the intersystem crosslinking, 
and the PS in this state can react directly with molecu-
lar oxygen. This reaction gives two forms of oxygen 
singlet (which are highly reactive oxygen species) that 
can directly attack biomolecules as amino acid resi-
dues, unsaturated lipids and nucleobases. Most studies 
have pointed out that the cell death is mainly mediated 
by the last one mechanism [131] 
The classic model of photosensitizers can be found 
in the tetrapyrrole ring (porphyrins, chlorins) which 
have been extensively studied in photochemistry. In 
this way, porphyrin derivatives were approved for hu-
man use in PDT for the treatment of several types of 
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Fig. (15). Chemical structure of RAPTA derivatives. 
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Fig. (16). Summary of the putative action mechanism of Ru compounds. 
Table 4. Structure, cell line, IC50 values of different ruthenium complexes. 
Structure Cell line IC50 (µM) Reference 
Ru N
N
Cl
PPh3
PPh3
CF3SO3
 
A2780 
MCF7 
HeLa 
J774  
0.54 ± 0.1 
5.4 ± 2.0 
3.6 ± 1.1 
1.9 ± 0.1 
[114] 
1a 
CN
NOH
O  
518A2 
518A2 
HL-60 
HL-60 
Kb-V1/Vbl 
Kb-V1/Vbl 
MCF-7/Topo  
MCF-7/Topo 
94 (24h) 
16 ± 3.4 (48h) 
11 ± 2.4 (24h) 
9 ± 1.4 (48h) 
9 ± 2.4 (24h) 
6 ± 1.4 (48h) 
50 (24h) 
1.5 ± 0.3 (48h) 
[115] 
1b 
CN
NO
O  
518A2 
518A2 
HL-60 
HL-60 
Kb-V1/Vbl 
Kb-V1/Vbl 
MCF-7/Topo 
MCF-7/Topo 
45 ± 1.5 (24h) 
50 ± 6.2 (48h) 
33 ± 4.2 (24h) 
32 ± 3.3 (48h) 
46 ± 5.6 (24h) 
20 ± 4.8 (48h) 
48 ± 5.8 (24h) 
11 ± 3.8 (48h) 
[115] 
2a 
CN
NOH
O
i-Pr
Ru
Cl
Cl
 
518A2 
518A2 
HL-60 
HL-60 
Kb-V1/Vbl 
Kb-V1/Vbl 
MCF-7/Topo 
MCF-7/Topo 
31 ± 2.3 (24h) 
13 ± 4.2 (48h) 
2 ± 1.1 (24h) 
0.8 ± 0.25 (48h) 
50 (24h) 
3 ± 0.7 (48h) 
50 (24h) 
0.2 ± 0.14 (48h) 
[115] 
2b 
CN
NO
O
i-Pr
Ru
Cl
Cl
 
518A2 
HL-60 
Kb-V1/Vbl 
Kb-V1/Vbl 
MCF-7/Topo 
MCF-7/Topo 
60 ± 1.7 (48h) 
95 ± 5 (48h) 
59 ± 3.1 (24h) 
31 ± 4.7 (48h) 
49 ± 3.9 (24h) 
29 ± 3.4 (48h) 
[115] 
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(Table 4) contd…. 
Structure Cell line IC50 (µM) Reference 
3a 
CN
NHO
O
Ru
Cl
Cl
 
518A2 
518A2 
HL-60 
HL-60 
Kb-V1/Vbl 
Kb-V1/Vbl 
MCF-7/Topo 
MCF-7/Topo 
3 ± 0.3 (24h) 
2.2 ± 0.2 (48h) 
1.3 ± 0.02 (24h) 
1 ± 0.2 (48h) 
20 ± 4.6 (24h) 
7 ± 1.5 (48h) 
75 ± 13.7 (24h) 
7 ± 2.7 (48h) 
[115] 
N
N
H
H2N
Ru
Cl
 
SiHa 37.1 [116] 
N
N
H
H2N
Ru
Cl
i-Pr
 
SiHa 16.91 [116] 
 
N
N
H
H2N
Ru
Cl
 
SiHa 11.11 [116] 
Ru
NN
Cl
N
CF3
F
F3C
F  
HeLa 
HEp-2 
7T 
HCT 116 
H460 
MDA-MB-485 
0.230 ± 0.053 
0.226 ± 0.002 
0.330 ± 0.037 
0.249 ± 0.010 
0.300 ± 0.033 
0.297 ± 0.015 
[117] 
Ru
NN
Cl
N
CF3
Cl
F3C
Cl  
HeLa 
HEp-2 
7T 
HCT 116 
H460 
MDA-MB-485 
0.103 ± 0.006 
0.108 ± 0.015 
0.109 ± 0.006 
0.106 ± 0.009 
0.117 ± 0.004 
0.123 ± 0.018 
[117] 
Ru
NN
Cl
N
I
I  
HeLa 
HEp-2 
7T 
HCT 116 
H460 
MDA-MB-485 
0.203 ± 0.025 
0.180 ± 0.015 
0.212 ± 0.020 
0.180 ± 0.001 
0.208 ± 0.018 
0.329 ± 0.174 
[117] 
N
SNH
N
Ru
Cl
+
Cl-
 
HeLa 
A2780 
A2780cisR 
HFL-1 
7.42 ± 0.01 
9.65 ± 0.01 
12.95 ± 0.04 
18.48 ± 0.02 
[118] 
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(Table 4) contd…. 
Structure Cell line IC50 (µM) Reference 
N
SNH
N
Ru
Cl
+
Cl-
 
HeLa 
A2780 
A2780cisR 
HFL-1 
2.55 ± 0.01 
2.49 ± 0.02 
0.93 ± 0.02 
6.27 ± 0.01 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
11.42 ± 0.02 
6.99 ± 0.02 
2.08 ± 0.01 
6.43 ± 0.02 
 
[118] 
N
S
COOEt
N
H
N
Ru
Cl
+Cl-
Cl
Cl  
HeLa 
A2780 
A2780cisR 
HFL-1 
3.65 ± 0.03 
12.21 ± 0.03 
12.62 ± 0.01 
181 ± 0.89 
[118] 
N
SNH
N
Ru
Cl
+Cl-
Cl
Cl
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
7.98 ± 0.01 
50.08 ± 0.03 
55.58 ± 0.03 
47.33 ± 0.32 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
Cl
Cl
COOEt
 
HeLa 
A2780 
A2780cisR 
HFL-1 
0.84 ± 0.25 
2.86 ± 0.01 
6.06 ± 0.02 
4.52 ± 0.01 
[118] 
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Structure Cell line IC50 (µM) Reference 
N
SNH
N
Ru
Cl
+Cl-
HO
 
HeLa 
A2780 
A2780cisR 
HFL-1 
19.40 ± 0.03 
6.13 ± 0.25 
6.19 ± 0.01 
49.40 ± 0.31 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
HO
 
HeLa 
A2780 
A2780cisR 
HFL-1 
6.87 ± 0.23 
5.25 ± 0.03 
4.24 ± 0.01 
7.30 ± 0.03 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
7.95 ± 0.03 
6.97 ± 0.33 
6.80 ±0.05 
6.47 ± 0.23 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
2.26 ± 0.03 
5.12 ± 0.03 
1.33 ± 0.02 
13.88 ± 0.03 
 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
O
COOEt
 
HeLa 
A2780 
A2780cisR 
HFL-1 
5.66 ± 0.01 
9.47 ± 0.03 
3.14 ± 0.01 
4.27 ± 0.03 
[118] 
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Structure Cell line IC50 (µM) Reference 
N
SNH
N
Ru
Cl
+
Cl-
O
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
7.88 ± 0.01 
4.54 ± 0.01 
2.25 ± 0.03 
3.84 ± 0.01 
 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
Cl
 
HeLa 
A2780 
A2780cisR 
HFL-1 
11.15 ± 0.01 
6.13 ± 0.02 
2.14 ± 0.04 
6.32 ± 0.02 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
Cl
O
 
HeLa 
A2780 
A2780cisR 
HFL-1 
2.69 ± 0.01 
2.26 ± 0.03 
2.14 ± 0.04 
36.61 ± 0.48 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
Cl
 
HeLa 
A2780 
A2780cisR 
HFL-1 
6.81 ± 0.03 
7.70 ± 0.12 
2.77 ± 0.01 
13.69 ± 0.01 
 
[118] 
N
SNH
N
Ru
Cl
+
Cl-
Cl
COOEt
 
HeLa 
A2780 
A2780cisR 
HFL-1 
1.72 ± 0.01 
3.75 ± 0.02 
3.76 ± 0.03 
2.81 ± 0.03 
[118] 
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(Table 4) contd…. 
Structure Cell line IC50 (µM) Reference 
Fe
Ru
Cl
Cl
P
Ph
Ph O
N
H
H
N
O
Me
 
A2780 
A2780cisR 
HEK-293 
113 ± 6 
112 ± 16 
232 ± 32 
[119] 
Fe
Ru
ClCl
P
Ph
Ph O
N
H
H
N
O
NH2
 
A2780 
A2780cisR 
HEK-293 
195 ± 4 
103 ± 10 
247 ± 18 
[119] 
Fe
Ru
ClCl
P
Ph
Ph O
N
H
H
N
O
NH
 
A2780 
A2780cisR 
HEK-293 
132 ± 18 
96 ± 6 
90 ± 5 
[119] 
Fe
Ru
ClCl
P
Ph
Ph O
N
H
H
N
O
NHPh
 
A2780 
A2780cisR 
HEK-293 
19 ± 3 
25 ± 1 
20 ± 1 
 
[119] 
Fe
Ru
ClCl
P
Ph
Ph O
N
H
H
N
O
N
 
 
A2780 
A2780cisR 
HEK-293 
69 ± 12 
90 ± 7 
61 ± 2 
[119] 
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Structure Cell line IC50 (µM) Reference 
N
N
H
Ru
H2N
Cl
R4
R3R2
R1
R6 R5
Cl
R1
R4
R6
R5
R2
R3
C6H6 (1)
p-MeC6H4Pr (2)
C6Me6 (3)
=
 
SiHa 37.10 (1) 
16.91 (2) 
11.11 (3) 
[120] 
Ru
N
N
N
N
N
N
N
N
N
2+
 
CT26 
A549 
15.9 ± 2.4 
21.0 ± 1.7 
[121] 
Ru
N
N
N
N
N
N
N
N
N
2+
N N
N
 
CT26 
A549 
5.3 ± 1.1 
3.8 ± 0.4 
[121] 
N
N
N N
N
N
NN Ru
2+
 
CT26 
A549 
11.3 ± 2.0 
13.4 ± 3.0 
 
 
[121] 
N
N
N
N
N
N Ru
N
NN
N
2+
 
CT26 
A549 
5.5 ± 0.90 
6.5 ± 0.5 
[121] 
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(Table 4) contd…. 
Structure Cell line IC50 (µM) Reference 
N
N
N
N
Ru
Cl
+ PF6-
 
A549 
MDA-MB-231 
HeLa 
MRC5 
6.9 ± 2.9 
0.7 ± 0.3 
0.6 ± 0.5 
0.4 ± 0.1 
[122] 
N
N
N
N
Ru
Cl
+ PF6-
 
A549 
MDA-MB-231 
HeLa 
MRC5 
> 100 
> 100 
> 100 
> 100 
[122] 
N
N
Ru
Cl
+ PF6-
N
NH
 
A549 
MDA-MB-231 
HeLa 
MRC5 
24.5 ± 0.1 
3.7 ± 0.3 
4.9 ± 0.1 
3.2 ± 0.1 
[122] 
N
N
N
NRu
+
   
HeLa 
Hep-G2 
BEL-7402 
A549 
A549/CDDP 
LO-2 
> 100 
> 100 
> 100 
> 100 
> 100 
> 100 
 
[123] 
N
N
N
NRu
+
 
HeLa 
Hep-G2 
BEL-7402 
A549 
A549/CDDP 
LO-2 
51.4 
69.2 
45.3 
79.2 
> 100 
> 100 
 
[123] 
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Structure Cell line IC50 (µM) Reference 
N
N
N
NRu
+
 
HeLa 
Hep-G2 
BEL-7402 
A549 
A549/CDDP 
LO-2 
3.3 
5.6 
7.4 
3.7 
4.1 
10.2 
[123] 
NO
N
X
Ru
H
CO
PPH3
H3PP
 
HeLa 
 
MCF-7 
21.0 ± 0.6 (X=O) 
18.0 ± 0.5 (X=S) 
6 ± 1 (X=O) 
2 ± 1 (X=S) 
[124] 
H
N
Cl
ClO
ORu
P
P
P
P
PF6
 
Hep-G2 
MCF-7 
MO59J 
GM07492A 
7.6 ± 0.9 
47 ± 6 
8 ± 2 
2 ± 1 
[125] 
O
ORu
P
P
P
P
CH3
CH3
CH3
PF6
 
Hep-G2 
MCF-7 
MO59J 
GM07492A 
5 ± 3 
9 ± 3 
6.5 ±0.2 
6 ± 2 
[125] 
Ru
NCl
Cl
O
O
F
F
F
F F
( )n
1: n = 7
2: n = 9  
SW480 
 
LS174T 
>200 (1) 
>200 (2) 
41.4 ± 2.6 (1) 
>500 (2) 
[126] 
N
O
Ru
Cl
Cl
S
S
O
O
O
H
N OH
OH
 
BEL-7404 
A549 
MGC80-3 
HeLa 
Hep-G2 
BEL7402 
HL-7702 
7.4 ± 0.4 
10.8 ± 0.2 
10.4 ± 0.1 
9.0 ± 0.6 
16.2 ± 0.7 
14.7 ± 0.3 
69.2 ± 0.3 
 
[127] 
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cancer, macular degeneration, etc. In the Fig. (17), the 
structure of porfirmer sodium (Photofrin®) is presented 
which is a Haematoporphyrin derivative, used in the 
treatment of bladder cancer and non-small cell lung 
carcinoma [132]. 
OH
N
O-
O
N
O-
O
O
HO
-O
O
-O
O
HN
N
N
N
H
NH
NH
Na+
Na+
Na+
Na+
!"#$%&'#()"*%+&  
Fig. (17). Porfimer sodium, commercially known as Pho-
tofrin®. Drug currently approved by health organism for 
PDT. 
 
As previously highlighted the ruthenium complexes 
have great potential in the medicinal chemistry as anti-
cancer agents. Based on previously analysis, two ap-
proaches have been proposed in the development of the 
Ru related photosensitizer for PDT. The first one is the 
use of well-known porphyrin photosensitizers func-
tionalized with ruthenium moieties (mostly organomet-
allic) and the second one is to obtain ruthenium com-
plexes that have photosensitizer behavior per se 
(polypyridyl complexes are the most studied). 
3.5. Porphyrin Related PS 
Schmitt et al. described that the addition of the Ru-
arene moiety to tetrapyridylporphyrin ring increased 
the hydrophilicity and the uptake of the compounds in 
Me300 melanoma cell line. Besides, the effect on the 
cells was independent of the arene ligand and the pho-
todynamic behavior was not affected by the incorpora-
tion of Ru (Fig. 18) [133].  
N
H
N N
H
N
N
N N
N
Ru
Cl
Cl
R
Ru
Cl
Cl
R
Ru
Cl
Cl
R
Ru
Cl
Cl
R
O
OO
O
R1
R2
R3
R4
R5
 
Fig. (18). Porphyrin substituted with Ru-arenes. 
Later, Schmitt compared the effect of the arene 
ligand derivation in monopyridylporphyrin (mpp) and 
tetrapyridylporphyrin (tpp) compounds, and also stud-
ied the effect of the isomer used (3-pp and 4-pp) (Fig. 
19), in Me300 cell line. The cytotoxicity at 72h, with-
out light stimulation revealed that monosubstituted 
porphyrins exerted a weak effect on cellular prolifera-
tion, while the tetrasubstituted analogues demonstrated 
an IC50 value in the 10-20 µM range. This cytotoxic ef-
fect can be related to DNA synthesis inhibition. In rela-
tion to the photosensitizer behavior the isomer in the 
position 3 showed a better performance, since it needed 
low light radiation (0.5J/cm2) and low concentrations 
(5µM) to decrease the cell viability significantly.In 
conclusion they propose a molecule tretracoordinated 
with Ru-arene in the position 3 of the tetrapyridylpor-
phyrin moiety, as was proposed very interesting candi-
date for PDT[134]. 
Davia reported the synthesis of a compound porphy-
rin was functionalized in three positions with vainillin 
derivative, and the fourth position was coordinated 
with Ru- polypyridyl complexes. The results showed a 
high DNA binding rate for the compound and cell 
death at 10µM and activation through 60W tungsten 
bulb but importantly highlighted the lack of cytotoxic 
effects without light activation [135] (see Fig. 20) 
A Ru porphyrin (RuP) compound increased the cy-
totoxicity of AY27 cell line (rat bladder cancer) at 20 
µM through necrosis pathway. However, there is not a 
big difference between dark toxicity and photoactivated 
toxicity with 15.6j/cm2 (17% and 14% cell viability 
compared to basal, respectively). Despite the genera-
tion of singlet oxygen the compound does not have 
good spectral properties to act as photosensitizer. Nev-
ertheless, RuP has lower IC50 compared with cisplatin 
[136] (Fig. 21). 
Pernot et al. evaluated the anticancer in vivo effects 
of two arene ruthenium porphyrin compounds (Rut1 
and Rut4, see Fig. 22) on a mice model with ectopic 
human oral carcinoma xenograft. The results depicted 
that the presence of the Ru groups enhanced the pho-
todynamic efficiency and Rut4 had a better perform-
ance. Associated with biodistribution high concentra-
tions of Ru were found in the liver, kidney, spleen and 
plasma maybe due to the reticuloendothelial system 
elimination. Varying concentrations 1.45 and 1.50% of 
the administered dose were found in the tumor during 
24 - 96h post injection. The subcellular distribution of 
the complex was found in the cytoplasm and not in the 
nucleus as expected for the Ru compounds [137]. 
The wide range of studies related to ruthenium 
chemistry found that some complexes have photo-
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Fig. (19). Arene ligand derivation in monopyridylporphyrin (mpp) and tetrapyridylporphyrin (tpp) compounds. 
 
HNN
NNH
N
HO
OCH3
H3CO
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N
N
N
N
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Fig. (20). Porphyrin functionalized with vanillin derivative 
and polypiridyl Ru complex. 
 
NN
NN
CH3
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H3C
CH3 H3C
CH3
H3C
CH3
Ru CO
 
Fig. (21). Structure of Ru-Porphyrin. 
 
physical properties which can be useful in PDT as pho-
tosensitizers. Different groups have been investigating 
with promising results. 
Gasser and co-workers [138] reported a pool of six 
complexes of Ru(II), 2,2’-bipyridine and dipyrido[3,2-
a:2’,3’- c]phenazine (dppz). Substituents as NH2, OMe, 
OAc, OH, CH2OH and CH2Cl were added on dppz 
moiety (Fig. 23). The complexes showed a oxygen sin-
glet quantum yield varying in the range of 50 - 94% 
and showed good stability in human plasma after 48h 
incubation. Cytotoxicity assays were carried out show-
ing low effect on Hela (cervix cancer) and MRC-5 
(normal phenotype) cell lines in dark (without light 
stimulation), however, when the cells were light-
radiated (9.27 J/cm2 at 420 nm), the IC50 value ranged 
between 2.0 and 20.5 µM, for the complexes 1,2,4 and 
6. The complexes 1 and 2 induced a DNA photocleav-
age effect at 10, 30, and 50 µM concentration. This 
effect can be correlated with high binding affinity of 
the complexes by the DNA.  
The design and synthesis of three highly charged ru-
thenium(II) polypyridyl complexes were reported by 
Chao, Gasser and co-workers. The complexes demon-
strated high phototoxic effect on 2D and 3D Hela cells 
models. Complexes Ru1, Ru2 and Ru3 (Fig. 24) had 
low dark toxicity with IC50 valu ranged between 300 - 
400 µM in the monolayer and greater than 500 µM in 
the 3D model. After ethe photoactivation the IC50 val-
ues were 1.1, 2.2 and 2.9 µM in the monolayer system, 
and in the case of the spheroids for one photon PDT, 
the IC50 values were 10.1, 15.4, 21.2 µM and 1.9, 5.4 
and 7.2 µM for two photon PDT. Besides, the results 
showed that the complexes were up taken via endocy-
tosis and suffer lysosomal accumulation [139]. 
Glazer et al. reported the synthesis of two ruthe-
nium complexes with bathophenanthroline and batho
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Fig. (22). Rut1 and Rut4 structures. 
 
N
N
N
N N
N
R
N
N
Ru
NH2 (1)
OMe (2)
OAc (3)
OH (4)
CH2OH (5)
CH2Cl (6)
2+
 
Fig. (23). Complexes of Ru(II) and 2,2’-bipyridine and 
dipyrido[3,2-a:2’,3’- c]phenazine (dppz). 
 
phenanthroline disulfonate (Fig. 25) and the effects of 
these complexes on jurkat, HL60 and A549 cell lines. 
The compound with bathophenantroline induced dark 
cytotoxicity (IC50 ranged 0.62 to 3.15 µM) for three cell 
lines and even lower after irradiation with visible light. 
This complex was located at mitochondrial level, caus-
ing an impairment in the mitochondrial function lead-
ing to death mediated by necrosis. 
N
N
N
N
N
N
Ru
Ru1: R = N(CH3)3
Ru2: R = N(CH2CH3)3
Ru3: R = N(CH2CH2CH2CH3)3
8+
R
R
R
R
R
R
 
Fig. (24). Ru1, Ru2 and Ru3: two photon activated photo-
sensitizer. 
The sulfonated analogue had a very low dark toxic-
ity (IC50 greater than 300 µM) while the photoactiva-
tion reduced the IC50 value to a range of 3.3 to 17.3 
µM. The main mechanism of action observed after 
light stimulation was apoptosis. In addition, both com-
plexes exerted photocleavage of the DNA [140]. 
On the other hand, Fig. (26) shows the summary of 
the main mechanism of action involved in the antitu-
mor properties of Ru compounds using in the PDT 
therapies. 
N
N
N
N
N
N
Ru
2+
N
N
N
N
N
N
Ru
SO3-
SO3-
SO3-
SO3-
SO3-
-O3S
4-
 
Fig. (25). Ru-bathophenanthroline and Ru-bathophenan-
throline disulfonate complexes. 
4. COPPER COMPLEXES 
Copper is an essential element associated with bio-
logical pathways since it acts as cofactor in most aero-
bic organisms [141]. Copper-based complexes have 
been studied because it has been shown that endoge-
nous metals are less toxic for normal cells than for can-
cer cells. Moreover, normal and tumor cells respond 
differently to copper and this is the major development 
of copper complexes having antiproliferative character-
istics. 
Even though copper level in the human organism is 
strictly controlled, high serum and tissue levels of Cu 
were found in many types of human cancers including 
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breast [142], prostate [143], colon [144], lung [145] 
and brain cancer [146]. The reasons for this phenome-
non are connected to the important function that copper 
plays in angiogenesis [147], which is essential for 
growth, invasion and metastasis [148]. Therefore, it has 
been claimed that copper chelators may have high 
therapeutic value acting as antiangiogenic molecules 
[149].  
Several antitumor studies have postulated copper 
complexes as anticancer or anticarcinogenic agents in 
in vitro and in vivo systems [150-152]. In particular, it 
has been demonstrated that copper thiosemicarbazones 
have antitumor activity [153] and developments in this 
area are still in progress [154,155]. In fact, novel cop-
per thiosemicarbazone complexes showed cell growth 
inhibition, apoptosis induction and cell cycle arrest on 
cisplatin-resistant neuroblastoma cells [155].  
It has been shown that a dimeric copper complex of 
the unsubstituted pyridoxal thiosemicarbazone induces 
apoptosis and arrest the cell cycle significantly on two 
human lymphocytes (CEM and U937 cell lines), but it 
is inactive on K562 human lymphoblasts in vitro and 
on TLX5 lymphoma in vivo. However, copper com-
plexes with N-substituted pyridoxal thiosemicarba-
zones did not produce inhibition on cell proliferation 
on the aforementioned cell lines [156]. 
Isoflavones are a type of naturally occurring isofla-
vonoids which act as antioxidants because of their abil-
ity to trap singlet oxygen showing antitumor activity 
[157,158]. Copper(II) complexes showed moderate 
cytotoxicity against five human cancer cell lines, with 
IC50 values in the 10−50 µM range [159] pointing out a 
benefit of the complexation of these ligands, since the 
complexes showed a stronger inhibitory effects than 
free isoflavones or metal ions. Moreover, complexes 
provoked a significant G(2)/M phase arrest, which de-
veloped early apoptosis.  
Hesperetin and apigenin are biologically active fla-
vonoids which have been investigated as antitumor 
drugs against breast cancer and hepatoma cell lines 
[160]. Copper complexes with hesperetin and apigenin 
showed growth inhibition of SGC-7901 and HepG2 
cell lines in comparison to the free ligands [161].  
In a recent study, it was demonstrated that a Cu(II) 
complex with quercetin can cleavage plasmid DNA 
generating single and double DNA strand breaks, inter-
calate the DNA strand and increase the level of reactive 
oxygen species which produce oxidative DNA damage. 
Moreover, induction of apoptosis has been observed 
along with a decrease in the levels of survivin protein 
expression and increase in caspase-3 on A549 cells 
[162]. 
This study previously reported the biological actions 
of a copper(II) complex with santonic acid. The com-
pound produced a cytotoxic effect on four cell lines 
(MC3T3-E1, UMR-106, Caco-2, TC7) displaying al-
teration in the nuclei and cytoplasm of treated cells 
[163].  
Moreover, the lowering blood pressure drug valsar-
tan coordinated with copper(II) through its carboxylate 
group giving rise to a binuclear compound, which 
showed antiproliferative activity toward two selected 
cell lines (normal MC3T3-E1 and tumor UMR-106) in 
the micromolar range, whereas valsartan itself had no 
effect up to 100 mM [164] (see Fig. 27 for a schematic 
representation of the complex). 
 
Fig. (26). Ruthenium compounds in the PDT anticancer therapies. 
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Fig. (27). Schematic representation of structure of copper(II) 
complex with valsartan. 
 
Copper complexes have been demonstrated to show 
potential as cytotoxic drugs in in vitro assays, however, 
there is little information on the cellular mechanisms of 
action or the molecular targets implicated (see Fig. 28 
for a schematic summary). 
Previously, it has been shown that copper binds to 
DNA and interacts with DNA in a non-covalent way, 
through intercalation, electrostatic forces, and groove 
binding [6]. 
An example of the interaction of planar polycyclic 
containing copper compounds with DNA was shown 
for Casiopeinas TM. These mixed-chelate complexes 
carrying aromatic substituted diimine (phen or bipy and 
substituted analogs) showed antineoplastic properties 
(Fig. 29) [165,166].  
The authors described that Casiopeinas stacked be-
tween DNA bases produced a DNA breakup detected 
in either pUC19 plasmid or in HeLa cells [167,168]. 
Moreover, it has been demonstrated that only planar 
and unsubstituted ligands could intercalate into DNA 
 
Fig. (28). Schematic representation of molecular targets involved in antitumor activity of copper complexes. 
 
N N
H3C CH3
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O O
NO3
N N
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O O
NO3
N N
CH3
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O O
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N N
H3C CH3
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Fig. (29). Schematic structures of CASIOPEINAS™  compounds. 
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[169-171] whereas nonplanar aromatic heterocyclic 
ligands did not show intercalation properties [172,173]. 
That is why physicochemical properties, such as the 
planarity play important roles in the mechanism of in-
teraction with DNA [6]. On the other hand, Cu(II) 
complexes have been demonstrated to produce DNA 
oxidative cleavage due to their redox properties. Many 
copper complexes generated plasmid DNA cleavage 
through an oxidative pathway [170,174,175]. This phe-
nomenon was observed through a Fenton-type reaction, 
where hydroxyl radicals [176] or different metal-based 
radicals were formed, producing oxidation and the 
breakup of DNA [177]. After DNA injury, many cop-
per complexes trigger apoptotic cell death. Synthesis of 
proapoptotic or antiapoptotic proteins is deregulated as 
it was described for Cu(N9-ABS)(phen)2] (H2N9-ABS = 
N-(9H-purin-6-yl)benzenesulfonamide) which induced 
a rise in p53 protein and a reduction of Bcl-2 expres-
sion in Caco-2 cells [178]. On the other hand, recent 
research has demonstrated that the inhibition of topoi-
somerases is another mechanism of action of copper(II) 
compounds. These enzymes regulate the overwinding 
or underwinding of DNA generating a transient DNA 
break which allows the DNA to be untangled [179].  
Topoisomerase inhibitors have been postulated as 
important drugs for cancer chemotherapy treatments. A 
copper(II) complex of 2-furaldehyde oxime was found 
to injure topoisomerase activity by blocking the phos-
phorylation activation [180]. More recently, a copper 
salicylaldoxime, which effectively inhibited the L1210 
leukemia cells, restrained topoisomerase dimmer for-
mation with consequent induction of single-strand 
breaks in the DNA. A series of novel copper(II) com-
plexes with quinolinone Schiff bases induced cytotox-
icity and inhibition of DNA synthesis in HepG2 cells in 
a concentration and time-dependent fashion due to their 
topoisomerase inhibitory potential [181]. 
Copper complexes containing the planar heterocyc-
lic phenanthroline showed that they can bind selec-
tively to DNA by intercalation and electrostatic forces, 
and inhibit topoisomerase I, leading to apoptotic cell 
death in nasopharyngeal cancer cell line HK1 but not 
on normal NP69 cells [182].  
Proteasome inhibition is another mechanism by 
which copper complexes exert their antitumor activity. 
The proteasome is a large multiprotein complex located 
in both the nucleus and the cytoplasm. It degrades 
wanted or damaged proteins which are tagged with 
ubiquitin molecules. The polyubiquitin chain is recog-
nized by the proteasome, allowing it to degrade the 
tagged protein The proteasome is part of a major 
mechanism by which cells regulate many cellular func-
tions, such as proliferation, apoptosis, angiogenesis, 
and metastasis formation [183]. An excellent antican-
cer strategy is targeting the ubiquitin−proteasome 
pathway, since cancer cells are more vulnerable to pro-
teasome inhibition than normal cells [184], and cur-
rently, development of proteasome inhibitors is under 
exhaustive investigation. Several copper compounds 
have been investigated to selectively inhibit the protea-
some in vitro and in vivo in human leukemia cells, 
however proteasome is not inhibited in non-
transformed human natural killer cells under the same 
treatment [185]. Moreover, it has been established that 
certain types of organic ligands could bind to copper 
found inside the tumor cells and form proteasome in-
hibitors that lead to apoptosis [1]. Copper(II) com-
plexes with asymmetric ligands containing the meth-
ylpyridin-amino-methylphenol moiety have been 
shown to inhibit the proteasome in vitro and in vivo 
[186]. These compounds were studied in prostate can-
cer cells resulting in an induction of apoptosis associ-
ated with a significant proteasome inhibition. It has 
been suggested that these copper complexes can cross 
over the cell membrane transporting the copper ion in-
side the cell [187]. It has been observed that ternary 
complexes binding with 1,10-phenanthroline reduce 
proteasome activity before induction of apoptosis in 
MDA-MB-231 human breast cancer cells, as well as in 
PC- 3 human prostate cancer cells [188]. The hypothe-
sis is based on the fact that phenanthroline transports 
copper into the cancer cell, leading to direct protea-
some inhibition or oxidation of the proteasome.  
5. NEW PERSPECTIVES: DRUG DELIVERY 
SYSTEMS FOR ADMINISTERING ANTICAN-
CER RU, V, CU BASED DRUGS 
Certain pharmacological issues of drugs such as 
bioavailability, site specific targeting, degradation and 
solubility may be improved by the application of dif-
ferent drug delivery systems. Nanotechnology is ex-
pected to address some of the most important problems 
of conventional anticancer chemotherapy. Nanodrugs 
are promissory in cancer chemotherapy because of 
their selective access to cancer cells and tissues [189]. 
Low efficiency of transport processes of active species 
to biological targets has also improved because nanoes-
tructures have been designed and developed. They act 
as vectors for metallodrug or simply as protectors of 
active species of the complexes for amplifying their 
activities and reducing their degradation [190, 191]. 
Numerous molecules and macromolecules have 
been employed as drug delivery systems for metallo-
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drugs such as cyclodextrins, liposomes, lipid nanocap-
sules, proteins, carbon nanotubes, polymeric nanoparti-
cles and ceramic materials [192]. 
Actually, copper complexes are being stabilized into 
nano-formulations for improving their biological activ-
ity. Copper complexes containing inorganic ligands 
(Cu(NH4)2Cl4 and CuCl2) were loaded on a functional-
ized titania to obtain drug delivery systems. They were 
tested as toxic agents on different cancer cell lines, as 
well as on cisplatin as a reference material. It was 
found that independently of the copper complex and 
also the cell line used, low concentrations of each cop-
per compound were sufficient to kill almost 100 % of 
cancer cells. Both copper complexes alone as well as 
those loaded on TiO2 had higher toxic effect than cis-
platin [193]. 
Moreover, it has been shown that multivalent cop-
per(II)-conjugated phosphorus dendrimers and their 
mononuclear copper(II) complexes exerted potential 
antiproliferative properties against HCT116, MCF-7, 
OVCAR8 and U87 cell lines [194]. A direct associa-
tion was found between the number of terminal moie-
ties or the amount of copper complexed to the den-
drimer and the growth inhibitory effect. These results 
demonstrated that the number of terminal moieties and 
Cu atoms increased cytotoxicity. Therefore, burdening 
copper complexes onto nanoestructures improved the 
anticancer properties. However, there have only been a 
few reports on the nano-functionalization of anticancer 
copper complexes so far, which strongly promoted the 
investigation of different copper complexes as antican-
cer agents in nano-formulations. 
On the other hand, molecular vectors were designed 
to transport ruthenium complexes to cells with an addi-
tional protection against physiological degradation dur-
ing long circulation times. Since despite their high ef-
fectiveness, they are poorly stable in physiological 
conditions and are present short half-life times in aque-
ous media [192]. Three amphiphilic nucleoside-based 
ruthenium complexes, ToThyRu, HoThyRu and DoHu-
Ru were combined with a new organometallic ruthe-
nium complex, named AziRu and stabilized in POPC 
phospholipid formulations, which were stable for 
months and showed high in vitro antiproliferative ac-
tivity [195]. Another efficient drug delivery strategy, 
warranting high ruthenium content within the formula-
tion, presented long half-life in physiological media 
and enhanced cell uptake. Amphiphilic ruthenium ani-
onic complexes, based on the formation of stable 
nanoparticles with the cationic lipid 1,2-dioleyl-3-tri-
methylammoniumpropane chloride (DOTAP) showed 
IC50 values in the low µM range against MCF-7 and 
WiDr cells, thus, proving to be 10-20-fold more active 
than AziRu with a marked tendency to accumulate 
within, or in proximity of the nuclei (see Fig. 30 for a 
schematic representation) [196]. Moreover, Valente 
and co-workers [197] reported the synthesis of a D-
glucose end-capped polylactide ruthenium cyclopenta-
 
Fig. (30). Schematic graphic of accumulation whitin nuclei of amphiphilic ruthenium anionic complexes, based on the forma-
tion of stable nanoparticles with the cationic lipid 1,2-dioleyl-3-trimethylammoniumpropane chloride (DOTAP). 
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Table 5. The most prominent V, Cu and Ru compounds as antitumor agents. 
Name Structure Biological data References 
Metal complexes 
under clinical inves-
tigation 
   
NAMI-A 
N
NH
Ru
S
O
Cl
Cl
Cl
Cl
-
N
H+
NH
NAMI-A  
In a phase I study it was concluded that NAMI-A can be 
safely administered as a three hour i.v. infusion at a dose 
of 300 mg/m2/day for five days, every three weeks. In 
this study, one patient (total: 24 patients) with non-small 
cell lung cancer showed stable disease. 
[98] 
KP1019 
N
NH
N
HN
Ru
ClCl
ClCl
-
H+
N
HN
KP1019  
KP1019 showed promising results in a phase I clinical 
study. Five of six evaluable patients with solid tumours 
experienced stable disease. Only mild toxicities were 
observed and further investigation in phase II was sug-
gested. 
In contrast to NAMI-A, KP-1019 was also active at the 
primary tumour site 
[93, 95] 
Casiopeína IIgly  
N N
Cu
O NH2
O
CH3H3C
+
NO3-
[Cu(4,7 -dimethyl-1,10-phenanthroline)glycinate]NO3  
CasII-gly prevents malignant cells to continue with their 
life cycle, by inhibiting estrogen-mediated G1/S cell cy-
cle progression. The compound inhibited uncontrolled 
cell migration of cancer cells. 
Currently, CasII-gly is in the  phase I clinical trials.  
[165, 166] 
Metal complexes 
under preclinical 
investigation 
   
[VCp2Cl2] 
VCl Cl
 
This  metallodrug exhibiting a higher in vitro activity on 
several such us leukemias P388 and L1210, colon 38 and 
Lewis lung carcinomas, B16 melanoma, among others. In 
addition, in vivo studies revealed that vanadocene com-
pounds show significant antitumor properties in MOLT-4 
leukemia and human peripheral blood mononuclear cells 
[33] 
Metvan 
N
N N
N
V
O OSO3
 
METVAN induces apoptosis in human leukaemia cells, 
multiple myeloma cells and solid tumour cells derived 
from breast cancer, glioblastoma, ovarian, prostate and 
testicular cancer patients 
[40] 
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dienyl complex (RuPMC), which displayed IC50 val-
ues in the micromolar range against human MCF7 and 
MDA-MB-231 breast and A2780 ovarian adenocarci-
noma. Cellular distribution studies also showed that 
RuPMC was predominantly found in the nucleus and in 
the membrane. Encapsulation and delivery of cytotoxic 
ruthenium complexes within nanostructures have 
shown an advance in the enhance permeability and re-
tention effect, along with improvements in the cyto-
toxic effects, decrease in the harmfulness and eva-sion 
of complex structure degradation. However, further 
studies still have to be performed for developing novel 
mechanisms of drug delivery structures. 
Different drug delivery systems were described for 
vanadium compounds. Vanadocene dichloride could 
bind to transferrin and enhanced its anticancer activity 
in proliferating malignant cells that over-express trans-
ferrin receptors, indicating that transferrin plays an im-
portant role in the transport and targeted delivery of 
vanadocene dichloride into cancer cells [198]. An al-
ternative delivery system for a complex of vanadium 
(IV) with aspirin (VOAspi) was developed using 
poly(beta-propiolactone) (PbetaPL) films by one of. 
UMR106 osteosarcoma cells were used as a model to 
evaluate the anticarcinogenic effects of the VOAspi 
released from the PbetaPPL film. VOAspi-PbetaPL 
film inhibited cell proliferation in a dose-response 
manner and induced formation of approximately half of 
the thiobarbituric acid reactive substances, and an in-
dex of lipid peroxidation compared to that with free 
VOAspi in solution [199]. 
CONCLUSION 
The tremendous success of cisplatin, carboplatin 
and oxaliplatin in cancer chemotherapy provoked a 
great impulse of research in Inorganic Medicinal 
Chemistry. Scientific efforts have been specially de-
voted to solve problems such as side effects, and resis-
tance of platinum therapy. Intensive research has been 
done to design and develop novel non platinum-based 
metal anti-cancer drugs (Table 5). Different promising 
results have been reported in preclinical research for 
vanadium, ruthenium and copper complexes and sev-
eral of these metal based compounds have been already 
investigated in clinical trials. In the preclinical stage, 
the main mechanisms of action involved with the anti-
tumor properties of V, Ru and Cu compounds are: ROS 
generation, GSH/GSSG imbalance, cell cycle arrest, 
DNA fragmentation and apoptosis. Nevertheless, sev-
eral compounds have attracted attention based on 
modes of action different from that of cisplatin (cova-
lent binding to the DNA) whilst some metallocom-
pounds interact with other specific molecular targets 
different from DNA (such as tyrosinkinases, protea-
some, p53, etc). This research revealed new leadeing 
compounds for cancer therapy with well defined struc-
ture-activity relationships. In this order, the search of 
novel cellular targets including new inorganic and or-
ganic metal complexes is of great significance. 
Clinical research trials focused on copper and ruthe-
nium compounds showed that the copper compound 
Cas-GlyII was entered in phase I due to the interesting 
antitumor profile found in pre-clinical studies. Besides, 
the ruthenium agent NAMI-A acts by its anti-
metastasis properties rather than by conventional cell 
growth inhibitory effects. In addition, KP1019 in con-
trast to NAMI-A activated the primary tumour site. 
Currently, both Ruthenium complexes have com-
pleted phase II of clinical trials. Actually, clinical stud-
ies on vanadium, ruthenium and copper based drugs are 
ongoing and they will bring new candidates for modern 
chemotherapy in the next few years. 
Besides, this research in this field tried to overcome 
the problems existing between the therapeutic action 
and the adverse side effects of V, Ru and Cu com-
pounds. The balance towards the beneficial side is the 
crucial issue for the future use of these compounds as 
alternative therapies against cancer.  
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